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As a disease-modifying approach for Alzheimer’s
disease (AD), clioquinol (CQ) targets b-amyloid (Aß)
reactions with synaptic Zn and Cu yet promotes
metal uptake. Here we characterize the second-gen-
eration 8-hydroxy quinoline analog PBT2, which also
targets metal-induced aggregation of Aß, but is more
effective as a Zn/Cu ionophore and has greater
blood-brain barrier permeability. Given orally to two
types of amyloid-bearing transgenic mouse models
of AD, PBT2 outperformed CQ by markedly decreas-
ing soluble interstitial brain Aß within hours and im-
proving cognitive performance to exceed that of
normal littermate controls within days. Nontrans-
genic mice were unaffected by PBT2. The current
data demonstrate that ionophore activity, inhibition
of in vitro metal-mediated Aß reactions, and blood-
brain barrier permeability are indices that predict
a potential disease-modifying drug for AD. The
speed of recovery of the animals underscores the
acutely reversible nature of the cognitive deficits
associated with transgenic models of AD.
INTRODUCTION
Dysregulation of brain metal ion homeostasis, particularly Cu
and Zn, may be closely involved in the pathogenesis of AD and
its characteristic b-amyloid (Aß) neuropathology (Adlard and
Bush, 2006). Zn ions are released presynaptically (Fredericksonet al., 2006) and Cu ions postsynaptically (Schlief et al., 2005) into
the glutamatergic synaptic cleft, where they could precipitate Aß
and induce the formation of soluble toxic Aß oligomers (Barnham
et al., 2004; Bush et al., 1994; Huang et al., 1999; Lee et al.,
2002). Zn and Cu are indeed markedly enriched in plaque amy-
loid where they directly coordinate Aß (Dong et al., 2003; Opazo
et al., 2002). While Cu and Zn pool in the extracellular plaque, the
intracellular Cu stores are deficient in AD and could promote
the generation of Aß (Bayer et al., 2003; Phinney et al., 2003),
leading to a vicious cycle. Therefore, traditional high-affinity che-
lators that lower tissue metal levels are unlikely to be helpful in
remedying amyloid pathology, and may actually worsen the
biochemical features of Cu deficiency that characterize AD
(Adlard and Bush, 2006).
Clioquinol (CQ) is an 8-OH quinoline with moderate affinity for
Cu and Zn that inhibits metal-induced Aß aggregation and reac-
tive oxygen species generation in vitro (Cherny et al., 2001).
It lowers Aß production in cell culture through a mechanism
that involves raising cellular metal levels, thereby increasing
the levels of Aß-degrading matrix metalloproteinases (White
et al., 2006). Oral administration of CQ (30 mg/kg/d) to Tg2576
mice, a transgenic (Tg) model for AD (Hsiao et al., 1996), reduced
brain Aß burden by50% after 9 weeks, accompanied by a mod-
est increase in brain Zn and Cu levels (Cherny et al., 2001).
The effect of CQ treatment upon memory performance in Tg
mice has not previously been reported. A pilot phase IIa clinical
trial of CQ in AD patients showed evidence of slowing cognitive
deterioration and significantly lowered plasma Aß42 levels
(Ritchie et al., 2003). Further phase II/III studies were stalled by
difficulties in preventing di-iodo 8-hydroxy quinoline contamina-
tion upon largescale chemical synthesis. Additional studies in
Tg2576 mice and human volunteers showed that CQ entry intoNeuron 59, 43–55, July 10, 2008 ª2008 Elsevier Inc. 43
Neuron
Ionophore Rescue of Alzheimer Phenotypethe brain is limited, although upon brain entry it binds to amyloid
plaques (Opazo et al., 2006).
PBT2 is also an 8-hydroxy quinoline, but lacks iodine; it was
designed for easier chemical synthesis, higher solubility, and
increased blood-brain barrier permeability (K. Barnham, E. Gaut-
ier, G. Kok, and G. Krippner 2003, 8-Hydroxy Quinoline Deriva-
tives [World, Prana Biotechnology Ltd], PCT No. PCT/AU03/
00914, Publication No. WO2004007461, patent pending).
PBT2 was recently found to significantly reverse frontal lobe
functional deficits and to significantly lower cerebrospinal fluid
Aß42 in a 12-week phase IIa clinical trial in AD patients (Lannfelt
et al., 2008).
Here we interrogate the screening procedure that we used to
select PBT2 for clinical testing, since the mechanism of action of
this drug could yield insights into AD pathogenesis. We show
that PBT2 matched or exceeded the performance of CQ in a se-
ries of in vitro screening assays that we considered relevant to
the potential therapeutic mode of action. We then compare the
effects of PBT2 with those of CQ on behavior and neuropathol-
ogy in two well-established amyloid protein precursor (APP) Tg
mouse models of AD, the APPswe/PS1 dE9 (APP/PS1) (Jankow-
sky et al., 2001) and Tg2576 (Hsiao et al., 1996) models. Both
types of Tg mice overexpress APP bearing missense mutations
that cause AD in humans, but the APP/PS1 model additionally
expresses human presenilin with a deletion mutation (dE9) that
also causes AD. Both lines have progressive spatial learning def-
icits that are accompanied by rising cerebral Aß levels and in-
creasing amyloid plaques commencing at about 12 months of
age for Tg2576 and 6 months of age for the APP/PS1 model.
Apart from testing cognitive outcomes, experiments in two
models allow us to determine whether specific forms of Aß
change in register with cognitive improvement in both strains.
This is important because cognitive loss in APP Tg mice and in
AD itself is not a simple product of increased Aß concentration
or precipitate formation (McLean et al., 1999).
RESULTS
PBT2 Is a Superior Ionophore to CQ
Since recent findings suggest that increasing intracellular Cu or
Zn may lower Aß production (Bayer et al., 2003; Borchardt
et al., 1999; Cater et al., 2008; Phinney et al., 2003; White
et al., 2006), we appraised PBT2 and CQ for their ionophoric abil-
ity to promote the transport of Cu, Zn, and Fe across cell mem-
branes. PBT2 promoted markedly more uptake of Zn and Cu
than CQ in cell culture (Figure 1).
PBT2 Inhibits Aß:Cu-Mediated Redox Chemistry
and Synaptotoxicity In Vitro
We next assessed the ability of the compounds to mitigate the
effects of excess metal binding to Aß (hypermetallation) in vitro.
Both CQ and PBT2 significantly reduced the production of hy-
drogen peroxide by Aß:Cu complexes (Puglielli et al., 2005)
(CQ, 49.9%, p < 0.0001; PBT2, 59.2%, p < 0.0001), with
PBT2 providing a significantly greater inhibition than CQ (p =
0.01) (Figure 2A). Both compounds were effective in the dissolu-
tion of Zn-induced Aß1-42 precipitates (Huang et al., 1997)
(Figure 2B), with CQ significantly more effective than PBT2 at44 Neuron 59, 43–55, July 10, 2008 ª2008 Elsevier Inc.10 mM. Both compounds markedly inhibited Cu-induced Aß
dityrosine crosslinking (Figure 2C). PBT2 treatment of APP/PS1
brain slices resulted in a significant reduction in Zn detected in
thioflavin-positive plaques, as compared with buffer-treated sli-
ces or slices treated with a quinoline that does not coordinate
metals, 3-aminoquinoline (3-AQ) (Figure 2D). PBT2 and CQ
both significantly reversed the Aß-induced inhibition of long-
term potentiation (LTP) in hippocampal slices (Figure 3).
PBT2 Reverses the Alzheimer Phenotype within Days
PBT2 was well tolerated at doses up to 30 mg/kg/d, and for an
equivalent oral dose in mice (30 mg/kg), the brain-to-plasma
ratio of PBT2 was 24- to 31-fold higher than that of CQ, which
may be attributed to the latter’s lower plasma protein binding
(Table 1). Initially we tested PBT2 at 30 mg/kg/d by gavage for
9 weeks, as this was the protocol originally used for CQ (Cherny
et al., 2001). We found that PBT2 significantly decreased insolu-
ble Aß levels by30% (p = 0.04), soluble Aß by 37% (p = 0.006),
and plaque burden by z80% (p = 0.0008) in 15-month-old
Tg2576 mice (See Supplementary experimental procedures
and Figure S1, available online). By comparison, CQ decreased
insoluble Aß levels by 49%, increased soluble Aß levels by 52%,
and decreased plaque burden by 25% in 21-month-old Tg2576
mice (Cherny et al., 2001). PBT2 treatment did not alter metal
levels (Cu, Zn, Mn, or Fe) in the brain, liver, kidney, or plasma, es-
tablishing that, like CQ, PBT2 is not acting as a broad-based
chelator. Having established that PBT2 had comparable efficacy
to CQ in a 9 week protocol, we next studied how rapidly the
onset of Aß modulation occurred.
We tested the effects of CQ and PBT2 upon extracellular brain
Aß levels using in vivo microdialysis (IVM). Female APP/PS1 mice
(22 months of age) were given a single oral dose of either PBT2
(30 mg/kg, n = 3) or CQ (30 mg/kg, n = 2) following baseline
collections of interstitial fluid. Soluble interstitial Aß (AßISF)
decreased by z30%–40% over the 20 hr following treatment
with a single oral dose of CQ (Figure 4A). PBT2-treated animals
showed a markedly greater (z80%) decrease in AßISF (Overall
ANOVA, p = 0.05), with significant decreases at 8 (50%, p =
0.03), 16 (55%, p = 0.03), and 20 (81%, p = 0.0001) hr post-
treatment, as compared with baseline values (Figure 4A). To con-
firm the effect of PBT2 on AßISF levels, we repeated the IVM
experiment in male Tg2576 mice (18 months old, n = 5). A
single oral dose of PBT2 (30 mg/kg) resulted in a significant
decrease in Aß ISF at 8 (34%, p = 0.0003), 12 (33%, p =
0.0001), and 16 (32%, p = 0.01) hr posttreatment, as compared
with baseline values (Figure S2A). To gauge the entry of PBT2
into the brain interstitium, we measured the levels in microdialy-
sate in a parallel study of normal male, 12-week-old, C57Bl/6
mice (n = 5). Levels of PBT2 peaked at 4 hr postgavage, and
were not detectable by 12 hr (Figure S2B). The decrease in AßISF
in the Tg mice treated with PBT2 therefore began following
anz2–4 hr lag to compound exposure. Although these experi-
ments were compared with baseline readings from within the
same animals, we also determined that AßISF levels are normally
stable in untreated female APP/PS1 (n = 5) and untreated male
Tg2576 (n = 9) mice over the same intervals (Figure S2C).
These data demonstrate that PBT2 and CQ decrease soluble
AßISF levels within hours. To gain further insight into possible
Neuron
Ionophore Rescue of Alzheimer PhenotypeFigure 1. Ionophore Activity of CQ and PBT2
M17 human neuroblastoma cells were treated with 10 mM of Cu (A and D), Zn (B and E), or Fe (C and F) in the presence of varying concentrations of CQ (A–C) or
PBT2 (D–F), and cellular metal levels were measured after 5 hr. Data are means ± SEM; n = 3. *p < 0.05 for all comparisons; #p < 0.05 for comparisons to 0, 1, and
2 mM; **p < 0.05 for comparisons to 0 and 1 mM; ***p < 0.05 for comparisons to 1 mM.mechanisms for the PBT2 effect, we repeated the IVM experi-
ments in young APP/PS1 mice (n = 4, 3–4 months of age). These
animals, which lack the overt extracellular Aß deposits seen in
the older animals used in this study, also showed a significant
reduction in AßISF levels over the 20 hr following a dose of PBT2
(30 mg/kg) (Figure 4B). The drop in AßISF commenced 4 hr earlier
than in the older animals. We hypothesize that in young animals
without amyloid deposits, the clearance of Aß is more prompt
upon treatment with PBT2, since there is no dissociable reservoir
of precipitated Aß to replenish AßISF (Figure 7).
Evidence indicates that soluble extracellular Aß can affect
cognition (Cleary et al., 2005; Townsend et al., 2006). Since our
IVM data showed that PBT2 induces a rapid drop in AßISF, we in-
vestigated the effects of PBT2 and CQ treatment over a short
time frame in the Tg mice by testing them on the Morris Water
Maze (MWM). We treated 8-month-old female APP/PS1 mice
with CQ (30 mg/kg/d, n = 7), PBT2 (30 mg/kg/d, n = 7) or vehicle
(Standard Suspension Vehicle [SSV], n = 18) for a total period of
11 days (Table S1A) and monitored effects on the MWM. The
APP/PS1 mice exhibited marked and significant behavioral im-provement compared with SSV-treated Tg mice within 6 days
of treatment with PBT2, and showed both significantly enhanced
acquisition of the spatial learning task (Overall ANOVA F1,23 =
35.107, p < 0.0001, Figure 5A; for path length analysis see
Figure S3A; for comparison of tracking profiles between Day 1
and Day 6 see Figure S4; also see Movies S1 and S2) and en-
hanced retention of the task in a 24 hr probe trial (p = 0.008, Fig-
ure 6B; for full quadrant analysis see Figure S3B). There was also
a significant improvement for CQ-treated animals in the acquisi-
tion task (Overall ANOVA F1,23 = 16.195, p = 0.0005), but the
retention scores were not significantly different from those of
controls (p = 0.2, Figures 5A and 5B). The PBT2-treated animals,
compared with CQ-treated animals, performed significantly bet-
ter on the acquisition (Overall ANOVA F1,12 = 6.131, p = 0.03)
and retention (p = 0.05) of the task. We also treated non-Tg litter-
mates with CQ (30 mg/kg/d, n = 6), PBT2 (30 mg/kg/d, n = 6), or
vehicle (SSV, n = 7). Neither CQ nor PBT2 had an effect on the
performance of wild-type (WT) animals in the acquisition or
retention (Figures 5C and 5D) of the MWM, demonstrating that
the improvement in Tg mice was specific to the AlzheimerNeuron 59, 43–55, July 10, 2008 ª2008 Elsevier Inc. 45
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Ionophore Rescue of Alzheimer PhenotypeFigure 2. CQ and PBT2 Inhibit the Effects of Aß Hypermetallation In Vitro
(A) Inhibition of H2O2 generation. Effects of CQ and PBT2 (both 0.5 mM) upon H2O2 generation by Aß1-42:Cu (100 nM:200 nM) complexes in the presence
of dopamine (5 mM) are shown. (B) Dissolution of Zn-induced Aß1-42 precipitates. After incubation with ZnCl2 to induce aggregation, Aß1-42 aggregates
were incubated for 2 hr with CQ or PBT2, and residual aggregation was assayed by ThT fluorescence. Data are fluorescence levels normalized (100 AU) to
the absence of compound. (C) CQ and PBT2 inhibit Cu-mediated dityrosine crosslinking of Aß1-40 (9 kDa dimer) assayed by densitometric quantification of west-
ern blots probed with anti-dityrosine antibody. Data are densitometry levels normalized (100 AU) to the absence of compound. For (A–C), *p < 0.02 to baseline;
**p < 0.001 to baseline; #p < 0.05 to baseline; ##p < 0.05 between concentrations; ***p < 0.02. All data are means ± SEM; n = 3. (D) Reduction of plaque-bound Zn
by PBT2 treatment. Plaques in brain slices (200 mm) from an APP/PS1 mouse were stained with Zinpyr-4 and then treated with PBT2 (n = 17), SSV control solution
(n = 7), or the nonchelating quinoline 3-aminoquinoline (3-AQ, n = 12) for 5 min. Individual plaques were measured for signal intensity of this fluorophore before
and after drug treatment. There was a significant loss of Zn signal within thioflavin-positive plaques upon PBT2 treatment as compared with controls (**p < 0.001
PBT2 compared with either control).phenotype. Surprisingly, the PBT2-treated APP/PS1 mice were
superior to untreated non-Tg littermates in the acquisition of
the task (F1,12 = 12.25, p = 0.004) (Figure 5A). There were no sig-
nificant differences on the retention of the task. Comparison of
sham-treated WT and sham-treated Tg animals revealed that,
as expected, the Tg mice had deficits on the acquisition (ANOVA
F1,23 = 5.74, p = 0.02, Figure 5A) and retention (p = 0.05) of the
task, as compared with aged-matched control animals.
The most robust behavioral improvements were seen in
animals treated with PBT2. To explore the limiting dose required
to achieve this cognitive benefit and to determine whether im-
provements were possible in both genders, we utilized the
same experimental paradigm as above and treated male APP/
PS1 mice with either PBT2 at a lower dose (10 mg/kg/d, n = 6)
or vehicle (SSV, n = 7) (Figures 5E and 5F). An overall improve-
ment in the acquisition of the task was observed after the short-
term 11 day trial (F1,10 = 6.64, p = 0.028, Figure 5E), 24 hr after46 Neuron 59, 43–55, July 10, 2008 ª2008 Elsevier Inc.which there were no differences in the retention scores between
the two groups (data not shown). In order to determine if these
benefits were sustained, animals were maintained on PBT2 for
a total of 35 days, during the last week of which they were reas-
sessed on the MWM (see protocol in Table S1B). PBT2-treated
animals continued to show a significant improvement in the
acquisition of the task across the whole study (Overall ANOVA
F1,11 = 7.12, p = 0.022, Figure 5E), and the probe trial conducted
24 hr after the last 6 days of trials (Figure 5F) revealed a trend to-
ward improved retention of the task in the low-dose PBT2-treated
animals, compared with SSV-treated controls. Data such as
these, where a significant improvement is found in the acquisition
of the task, but not the retention of the task, may either represent
a specific effect on learning, but not recall, or it may be a conse-
quence of the cohort being too small to reveal the effect on recall.
The trend observed suggests that a larger cohort may have re-
vealed significant effects of PBT2 treatment on recall at 10 mg/kg.
Neuron
Ionophore Rescue of Alzheimer PhenotypeWe also tested the benefit of PBT2 on learning and memory in
a second type of APP Tg model. MWM studies using Tg2576
mice (female) demonstrated similar results to those in APP/
PS1 mice, with the PBT2-treated animals (n = 9) showing a signif-
icant improvement in performance as compared with SSV-
treated animals (n = 9) across the task (Overall ANOVA F1,15 =
4.9, p = 0.04) (Figure S5A), although the magnitude of the effect
(53% difference on trial 6) was not as large as that seen in
the APP/PS1 animals (85% difference on trial 6). While the
PBT2-treated Tg2576 animals demonstrated 100% improve-
ment in the probe trial as compared with SSV-treated con-
trols (Figure S5B), this did not reach statistical significance
(p = 0.18).
We assessed the brain tissue of a subset of the mice (n = 7
PBT2-, n = 7 CQ-, and n = 13 SSV-treated APP/PS1 mice) stud-
ied in the MWM experiments to determine whether the cognitive
improvements were associated with alterations in AD-related
parameters such as Aß burden, phosphorylation of tau, and syn-
aptic protein loss. We assayed insoluble Aß burden in the APP/
PS1 animals using surface-enhanced laser-desorption ionization
time of flight (SELDI-TOF) mass spectrometry, which allows for
the quantitation of individual Aß fragments. These data (Figure 6)
demonstrate that insoluble Aß40 (30% reduction, p = 0.06),
Figure 3. CQ and PBT2 Prevent Aß-Induced
Inhibition of LTP in Hippocampal Slices
(A and C) Field potential recordings of mouse hip-
pocampal slices, CA1 region, showing the effects
of stimulation upon field excitatory postsynaptic
potentials (fEPSPs) expressed as mean percent-
age of baseline (n = 12) ± SEM. The effects of
2 mM Aß42 ± 2 mM PBT2 or 4 mM CQ on fEPSPs
following tetanic stimulation is shown. PBT2 and
CQ were studied at the highest concentrations
that had no effect on LTP. The presence of
DMSO at the concentrations used in aCSF had
no effect on fEPSPs or LTP. (B and D) Percent
change in fEPSPs (±SEM) relative to baseline aver-
aged from data taken 55 to 60 min posttetanus.
*p < 0.05, unpaired t test.
Table 1. Brain and Plasma Concentrations of CQ and PBT2 (30 mg/kg) in WT and Tg Mice at 120 Min after Oral Administration
Strain Compound Brain Concentration (ng/g) Plasma Concentration (ng/ml)a Brain:Plasma Ratio
WT (female Bl6/SJL) CQ 161.0 ± 56.4 1084.1 ± 194.4 0.15 ± 0.06
PBT2 796.0 ± 513.5 216.9 ± 97.7 3.63 ± 1.31
Tg2576 (female Bl6/SJL) CQ 122.6 ± 25.2 1143.2 ± 343.8 0.12 ± 0.06
PBT2 318.1 ± 75.1 85.0 ± 14.9 3.74 ± 0.68
All data are presented as mean ± SD (n = 4 or 5). PBT2 exhibits much greater uptake into the brain, as compared with CQ, in both WT and Tg2576
animals.
a Plasma protein binding is >99.6% (n = 2) for CQ and 95.1% ± 0.8% (mean ± SD, n = 3) for PBT2.
Aß42 (41% reduction, p = 0.03), and
Aß43 (35% reduction, p = 0.11) were re-
duced with 11 days of PBT2 treatment
(30 mg/kg/d), whereas there was no con-
comitant effect on insoluble Aß in the
CQ-treated animals. We also assessed soluble oligomeric Aß
by western blot, utilizing oligomer-specific antibody A11. This
demonstrated a significant reduction in oligomeric Aß in PBT2-
treated animals (p < 0.05) and a significant increase in CQ-treated
animals (p < 0.05) as compared with SSV-treated controls
(Figure S6). Neither CQ nor PBT2 treatment affected APP levels
(data not shown).
We also assessed the effect of PBT2 treatment in the Tg2576
mice that were studied with the MWM. In contrast to the APP/
PS1 mice, different species of insoluble Ab assayed by SELDI-
TOF mass spectrometry decreased as a result of drug treat-
ment (Figure S7A). Significant decreases with drug treatment
(30 mg/kg/d, 11 days treatment) were observed in Aß1-37 (73%,
p = 0.03), Aß1-39 (79%, p = 0.04) and Aß2-46 (92%, p = 0.02).
Reductions in Aß1-40 (48%, p = 0.1) and Aß1-42 (25%, p =
0.49), as well as oxidized Aß1-42 (64%, p = 0.3), were also
seen with drug treatment, but did not reach statistical signifi-
cance (due to an outlier). In contrast to APP/PS1 animals, there
was no significant change in soluble oligomeric Aß detected by
A11 western blot (Figure S7B). Taken together, these data indi-
cate that AßISF is the only brain Aß species we could detect
that changes in register with cognitive improvement in both Tg
strains upon PBT2 treatment.Neuron 59, 43–55, July 10, 2008 ª2008 Elsevier Inc. 47
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Ionophore Rescue of Alzheimer PhenotypeFigure 4. PBT2 Reduces Interstitial AßISF Levels
in APP/PS1 Mice, as Ascertained by In Vivo Micro-
dialysis
(A) AßISF was assayed by western blot densitometry in
dialysates collected (4 hr collection bins) from the hippo-
campi of 14- to 24-month-old male and female APP/PS1
mice (CQ, n = 3; PBT2, n = 3). Animals were administered
a single gavage dose of either CQ (30 mg/kg) or PBT2
(30 mg/kg), and dialysates were collected over the subse-
quent 20 hr. The data are normalized to the average AßISF
concentration for the individual animal measured over the
8 hr prior to administration of the ionophore (mean Aß con-
centration for the group = 1.99 mg/l).
(B) AßISF was assayed by western blot densitometry in
dialysates collected (4 hr collection bins) from the hippo-
campi of 3- to 4-month-old female APP/PS1 mice (n = 4).
The data are normalized as in (A) (mean Aß concentration
for the group = 0.47 mg/l). Animals were gavaged with
PBT2 (30 mg/kg) and dialysates were collected over the
subsequent 20 hr.
(C) A representative western blot for Aß (arrow indicates
time of PBT2 administration).
Data are means ± SEM; one-way ANOVA, *p < 0.05,
**p < 0.01 compared with baseline, ***p < 0.0001 com-
pared with baseline.PBT2 Affects Both Tau Phosphorylation
and Synaptophysin Protein Levels
Hyperphosphorylation of tau and its accumulation in neurofibril-
lary tangles are also hallmark biochemical features of AD
(Grundke-Iqbal et al., 1986; Ihara et al., 1986). We assessed
both total tau and tau phosphorylated at Ser396, an epitope
that is abnormally phosphorylated in AD and which promotes
tau polymerization (Abraha et al., 2000), by western blot in the
APP/PS1 mice treated for 11 days in this study to gauge the
association of changes in these proteins with the observed im-
provements in cognition. Our data demonstrated a significant
reduction in phosphorylated tau in the animals treated for 11
days with PBT2 (soluble fraction: 56%, p = 0.005; insoluble
fraction: 38%, p = 0.01), which was not recapitulated in the
CQ-treated animals (insoluble: 8%, p = 0.6; soluble: +81% in-
crease, p = 0.02) (Figures 6C and 6D). Neither treatment elicited
a change in total tau levels (not shown). Longer-term treatment
(35 days) with a lower dose of PBT2 (10 mg/kg/d) in the APP/
PS1 mice resulted in a sustained decrease in soluble phosphor-
ylated tau (26%, p = 0.03), but the decrease in insoluble phos-
phorylated tau was not significant (27%, p = 0.4) (Figures 6E
and 6F). There were again no significant changes in levels of total
tau (not shown).
We also examined tau levels in the Tg2576 mice that were
treated with PBT2 (30 mg/kg/d) for 11 days. Unlike the effects
observed in the APP/PS1 model, significant changes in total
tau were observed. Total insoluble tau levels were decreased
with PBT2 treatment (24%, p = 0.003) while soluble tau was
increased (31%, p = 0.0006) (Figure S7C). In contrast, phos-
phorylated tau levels were not significantly different between
treatment groups (Figure S7D). Therefore, there was no concor-
dance between changes in tau and Ser396 phosphorylated tau48 Neuron 59, 43–55, July 10, 2008 ª2008 Elsevier Inc.levels in the two treated Tg mouse models and the observed
improvements in cognition.
Synaptophysin is a presynaptic marker that shows a regional
decrease of up to 50% in AD (Callahan et al., 1999; Sze et al.,
1997), which may be related to the accumulation of synaptotoxic
Aß species. We examined brain synaptophysin levels by western
blot in APP/PS1 animals given 30 mg/kg/d of either PBT2 or CQ
for 11 days. Both treatments significantly augmented the levels
of synaptophysin, with PBT2 (63%, p = 0.001) inducing a greater
increase than CQ (44%, p = 0.01) (Figure 6H). The lower dose of
PBT2 (10 mg/kg) in the APP/PS1 mice did not elicit a significant
change in synaptophysin levels (3%, p = 0.8, data not shown).
Synaptophysin levels were also significantly increased (38%,
p = 0.03) in the Tg2576 mice treated with 30 mg/kg PBT2 for
11 days as compared with the SSV-treated controls (Figure S7E).
DISCUSSION
We found that oral treatment with compounds based on the
8-OH quinoline scaffold induced a dramatic improvement in
learning and memory in Tg models of AD, accompanied by
marked inhibition of AD-like neuropathology. These outcomes
were rapid, with AßISF reduction occurring within hours, and
significant cognitive benefits were seen within days of the first
administration of compound.
While it has been previously shown that the responsible brain
lesions in these AD models are indeed reversible (Kotilinek et al.,
2002), the speed of the cognitive recovery upon treatment in our
studies is consistent with a lesion that could be analogous to
acute intoxication causing delirium. AD is not considered an
acute brain syndrome, but the possibility that there is a compo-
nent of delirium in the otherwise chronic disorder could explain
Neuron
Ionophore Rescue of Alzheimer PhenotypeFigure 5. PBT2 Improves the Performance of
APP/PS1 Transgenic Mice, but Not Nontrans-
genic Littermates, in the MWM
(A) Eight-month-old female APP/PS1 mice were
treated with SSV (n = 18), CQ (30 mg/kg, n = 7), or
PBT2 (30 mg/kg, n = 7) for a total period of 11 days
(see Table S1A), during which their performance on
the MWM was assessed. PBT2-treated animals
showed a significant improvement in the acquisition
of the task (ANOVA, p < 0.0001), as did CQ-treated an-
imals (ANOVA, p = 0.0005). PBT2-treated animals per-
formed significantly better than CQ-treated animals
(p = 0.03) and also significantly better (p = 0.004)
than SSV-treated age-matched WT controls (dashed
line). SSV-treated Tg animals demonstrated significant
deficits (p = 0.02) on this task as compared with
SSV-treated WT controls.
(B) Twenty-four-hour retention task. Retention was as-
sessed by the amount of time spent in the quadrant
where the escape platform was present for the acqui-
sition task. A significant improvement is shown in
PBT2-treated animals only (p = 0.008).
(C and D) Eight-month-old female WT littermates were
also assessed, and neither CQ (n = 6) nor PBT2 (n = 6)
had any effect on performance in the task, as com-
pared with SSV (n = 7).
(E and F) Effects of low-dose PBT2 (10 mg/kg, n = 6)
compared with SSV control (n = 7) in male APP/PS1
mice over a total period of 35 days (see Table S1B
for trial regimen; the line breaks represent a break in
trial tests). PBT2-treated animals showed an en-
hanced acquisition of the task (ANOVA, p = 0.022)
and a nonsignificant improvement in the retention
task. Data are mean times ± SEM; t test against
same-trial SSV control, *p < 0.003, **p < 0.0002,
#p < 0.01, ##p < 0.05.some well-known features of the disease, such as the rapid fluc-
tuations in cognitive performance (Ballard et al., 2001; Eikelen-
boom and Hoogendijk, 1999). In this regard, it is interesting
that commonly used anesthetics such as isoflurane, which is
associated with postoperative delirium, are a risk factor for AD,
and induce Ab production and apoptosis in vitro, which is res-
cued by CQ (Xie et al., 2007; Zhang et al., 2008). Our findings
underscore the possibility that acute intoxication is a feature of
Tg mouse models for AD, and may be an underappreciated facet
of the human disorder. From our current findings, the toxic
mediator of the acute cognitive deficits was most likely AßISF
(Figures 4 and S2), which was conspicuously decreased by
treatment in both strains of Tg mice and in approximate register
with the short time frame of cognitive improvement. This is in
agreement with previous studies that have implicated AßISF in
disease pathogenesis (Cirrito et al., 2005; DeMattos et al.,
2004). While we also observed decreases in other Aß species, in-
cluding Aß1-40 and Aß1-42, the decreases with PBT2 treatment
were not statistically significant across both Tg animal models.
Thus, the data presented here must be interpreted with the
caveat that we cannot eliminate the possibility that factors other
than AßISF have contributed to the rapid restoration of cognition
in our model. In addition to the changes in Aß, there were further
biochemical changes that may also have contributed to this cog-
nitive benefit. Notably, synaptophysin levels were also increased
in both Tg lines over the period of treatment (Figure 6), support-ing the likelihood that synaptotoxicity had been reversed. We
also observed a decrease in phosphorylated tau levels (Figure 6),
although this only occurred in the APP/PS1 mice and could not,
therefore, explain the cognitive improvement in Tg2576 animals.
The current data allow us to deduce valuable information
about factors that have increased the potency of PBT2 over its
predecessor CQ, which help elucidate the mechanism of action.
The in vitro screening protocols were based on a theory that
a candidate drug needs to neutralize the consequences of the
hypermetallation of Aß by Cu and Zn. To this end, both CQ and
PBT2 block the catalytic generation of H2O2 by the Aß:Cu com-
plex (Figure 2A), reverse Zn-mediated aggregation of synthetic
Aß (Figure 2B), and inhibit the formation of redox-mediated cova-
lently crosslinked soluble oligomers of Aß (Figure 2C). However,
neither compound was clearly superior in these in vitro assays in
a manner that could explain why PBT2 was more effective than
CQ in its cognitive benefits in Tg mice (Figure 5) and in decreas-
ing interstitial Aß (Figure 4) and insoluble Aß (Figure 6) in this short
time frame. Increased penetration of the blood-brain barrier,
possibly due to lower plasma protein binding, is certainly one
feature that is likely to explain the increased potency of PBT2,
although factors other than pharmacokinetics and blood-brain
barrier penetration are also likely to have contributed. Another
in vitro assay that clearly differentiated PBT2 as superior to CQ
was the ionophore assay (Figure 1). We previously reported
that CQ decreased Aß levels in neuronal cells by acting asNeuron 59, 43–55, July 10, 2008 ª2008 Elsevier Inc. 49
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PBT2 decreases Aß burden in APP/PS1 mice by SELDI-TOF mass spectrometry. (A) Sample spectra. (B) Quantitated data are average peak heights (±SEM) in all
animals. PBT2-treated animals demonstrate significantly lowered Aß1-42. *p = 0.03, t test, compared with SSV control. PBT2 decreases Ser396 phosphorylated
tau levels in APP/PS1 mice. Ser396 phosphorylated tau content was assayed by western blot and quantified by densitometry (normalized to SSV levels, 100 AU).
Levels of (C) insoluble phosphorylated tau and (D) soluble phosphorylated tau in APP/PS1 mice treated for 11 days with CQ or PBT2 (30 mg/kg/d) showing sig-
nificant reductions with PBT2 treatment. Levels of (E) insoluble phosphorylated tau and (F) soluble phosphorylated tau in APP/PS1 mice treated for 35 days with
PBT2 (10 mg/kg/d) showing significant reductions with PBT2 treatment. (G) Representative western blot of phosphorylated tau in the soluble brain fractions. *p <
0.05, t test, compared with SSV control. Data are means ± SEM. CQ and PBT2 increase synaptophysin levels in APP/PS1 mice. (H) Synaptophysin content was
assayed by western blot and quantified by densitometry (normalized to SSV levels, 100 AU), and showed significant increases with both CQ and PBT2 treatment.
(I) Representative western blot. Data are means ± SEM for all animals. *p = 0.03, **p = 0.009, t test, compared with SSV control.a Cu/Zn ionophore (White et al., 2006). Therefore, we suspect
that the superior ability of PBT2 to transport Cu or Zn ions into
the cell reflects a critical property of this class of potential thera-
peutic. Our in vitro assays cover multiple potential mechanisms
by which our candidate drugs could lower or detoxify brain Aß.
However, based upon our current findings, we propose the
following heuristic model for the mechanism of action of these
compounds (Figure 7).
We hypothesize that PBT2 and related compounds capture
metal ions from oligomerized and precipitated interstitial Aß, per-
haps forming redox-neutral ternary complexes (Figure 7). The
consequent dissolution of oligomerized Aß facilitates the clear-
ance of amyloid. PBT2 or CQ could also bring metals captured
from Aß oligomers into nearby cells, which could then increase
matrix metalloproteinase expression and thereby foster clear-
ance or degradation of AßISF (White et al., 2006) (see proposed
mechanism of action, Figures 7 and 2D). Similarly, liberated
Zn and Cu may restore the activities of interstitial metalloprotei-
nases that degrade AßISF (Strozyk et al., 2007). We hypothesize50 Neuron 59, 43–55, July 10, 2008 ª2008 Elsevier Inc.that the clearance of extracellular Aß resolves neuronal intoxica-
tion from pro-oxidant products like H2O2 (Figure 7), and so leads
to elevated synaptophysin (Figure 6) and improved synaptic
function (Figure 5). Additionally, the normalization of Zn and Cu
reuptake in the glutamatergic synapse may improve the function
of the NMDA receptor and restore LTP.
The ionophoric activity of CQ has been shown to activate
PI3K, ERK1/2, and JNK and also promote the phosphorylation
of glycogen synthase kinase-3; therefore, treatment with this
class of compound may decrease the hyperphosphorylation of
tau (White et al., 2006) (Figures 6C, 6D, and 7). Recent findings
have indicated that decreasing brain tau levels in APP Tg mice
uncouples Aß from downstream pathogenic mechanisms and
improves cognitive performance (Roberson et al., 2007). While
Roberson et al. (2007) did not differentiate between solution
states of brain tau, we found that PBT2 (but not CQ) decreased
insoluble and soluble phosphorylated tau in the APP/PS1 mice
(Figure 6) and insoluble total tau in the Tg2576 mice (although
soluble total tau was also increased in the Tg2576 model
Neuron
Ionophore Rescue of Alzheimer PhenotypeFigure 7. Proposed Mechanism of Action of PBT2
The figure shows a notional glutamatergic synaptic cleft with
Aß, Zn, and Cu being constitutively released from presynaptic
and postsynaptic origins. Zn and Cu are in an ionic form and
normally modulate NMDA receptor function (Frederickson
et al., 2006; Schlief et al., 2005). A. Soluble interstitial Aß (AßISF)
reacts with extracellular Zn and Cu to form protease-resistant
Aß oligomers and aggregates, which are in dissociable equi-
librium with the soluble species. PBT2 reacts with accessible
Zn and Cu, driving the dissociable equilibrium to the left, and
promoting soluble species. B. PBT2 also promotes the clear-
ance of Zn and Cu from the cleft, possibly by accessing the es-
tablished energy-dependent metal reuptake mechanisms that
appear to be failing in AD. C. Increased intracellular Cu (and
Zn, not shown here) leads to inhibited tau phosphorylation
and, through JNK, increased matrix metalloproteinase 2&3
(MMP2/3) activities (White et al., 2006). D. Zn and Cu, liberated
from aggregated Aß, increase the activities of interstitial met-
alloproteinases (Strozyk et al., 2007), such as neprilysin (NEP),
insulin degrading enzyme (IDE), and tissue plasminogen
activator (TPA). The increased amount of metalloproteinases
accelerates the degradation of AßISF.[Figure S7]). Therefore, if tau reduction contributes to the cogni-
tive improvements we observed, the mechanism may involve
preventing tau (either phosphorylated or nonphosphorylated)
from precipitating. The differential effect of CQ and PBT2 may
be due to the increased brain penetration of PBT2, or its in-
creased ionophoric activity and ability to impact upon tau phos-
phorylation, and warrants further investigation.
It is notable that despite the strong ionophoric properties of
PBT2 in cell culture, treatment of Tg mice in these studies did
not alter brain or peripheral metal levels. This is probably be-
cause PBT2 (and CQ) target Aß-bound metals that accumulate
in a very small relative volume (e.g., 6% in 12-month-old APP/
PS1 mice) (Stoltenberg et al., 2007) of the brain mass. Therefore,
a shift of metals from extracellular Aß aggregates into the paren-
chymal cells may not be reflected as a change in total tissue
metal levels, especially as homeostatic redistribution of the liber-
ated metals takes effect. This is a reassuring element of the
safety profile of the drug, since a perturbance of essential metal
biochemistry is an undesirable effect of stronger chelators.
Similarly to our findings, the lipophilic bivalent metal ion mod-
ulator, DP-109, induced marked reductions in brain Aß after 3
months of treatment in the Tg2576 Tg line (Lee et al., 2004). How-
ever, it is not known whether this compound has ionophoric
properties or if it improves cognitive performance. Genetic and
pharmacological Cu augmentation in two APP Tg models, which
reversed Cu deficiency induced by expression of the APP trans-
gene, resulted in a significant decrease in amyloid burden (Bayer
et al., 2003; Phinney et al., 2003). These reports support the hy-
pothesis that perturbed metal homeostasis underlies disease
progression in AD. However, oral Cu supplementation (8 mg/
day) for 12 months was not able to prevent cognitive deteriora-
tion in a double-blind placebo-controlled trial in AD patients
(http://www.alzheimer-bayer.de/alzh._st1.html, accessed May
18, 2008). We believe that compounds like CQ and PBT2 redis-
tribute metals from extracellular collections and restore intracel-
lular metal reserves where depleted, correcting not only theaccumulation of extracellular amyloid but also correcting multi-
ple biochemical deficits that are caused by dyshomeostasis of
essential Cu and Zn (reviewed in Adlard and Bush [2006]).
Existing FDA-approved drugs for the treatment of AD are all
based upon known neurotransmitter defects and are not consid-
ered to be disease-modifying. There are, however, several com-
pounds in preclinical and clinical development that aim to lower
Aß by a variety of mechanisms (Masters and Beyreuther, 2006).
The studies reported here demonstrate rapid and pronounced
benefits of ionophores on both AD-like neuropathology and cog-
nitive dysfunction in Tg models of AD. While further investiga-
tions are required to test the model of mechanism of action,
our findings support targeting synaptic metals, the factors that
lead to Aß oligomerization and toxicity, as possibly a more potent
disease intervention than systemically targeting the Aß molecule
or its generation. Results of a recent phase IIa clinical trial in AD
patients revealed a significant lowering of cerebral spinal fluid
(CSF) Aß1-42 and an improvement in two subtests of the Neuro-
psychological Test Battery (NTB) within 3 months of oral treat-
ment with PBT2. This further supports the predictive utility of
our drug discovery approach. PBT2 is progressing as a potential
disease-modifying treatment for AD.
EXPERIMENTAL PROCEDURES
Mice
Experimental groups of APP/PS1 [B6C3-Tg(APPswe,PSEN1 dE9)85Dbo/J]
and WT littermates were utilized in this study. Animals were treated with CQ
(30 mg/kg/d), PBT2 (10–30 mg/kg/d), or vehicle solution (SSV: 0.9% NaCl,
0.5% Na-carboxymethylcellulose, 0.5% benzyl alcohol, and 0.4% Tween-
80) at 8 months of age for a total period of either 11 or 35 days (see Table
S1 for outline), during which they were assessed in the MWM. The Tg2576
mouse line (encoding human APP695 with Lys670-Asn and Met671-Leu muta-
tions) (Hsiao et al., 1996) was also used, and animals were studied at 13.5
months of age. The Tg2576 mice were treated with either PBT2 (30 mg/kg/d)
or SSV for a total period of 11 days, during which they were subject to as-
sessment in the MWM. All drugs were administered daily by oral gavage,
and group sizes were from between 6 to 18 animals per treatment. ForNeuron 59, 43–55, July 10, 2008 ª2008 Elsevier Inc. 51
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months old) and Tg2576 (18 months) mice, in addition to young APP/PS1
(3.5 months) and young normal male C57Bl6/C3H (12 weeks) mice were
used. Group sizes were between two and nine animals per treatment.
All experiments were conducted according to the Australian Code of Prac-
tice for the Use of Laboratory Animals and were approved by the Institutional
Animal Experimentation Ethics Committee.
Ionophore Studies
M17 human neuroblastoma cells were plated overnight to 70% confluency (1
million cells) at the time of the experiment. All experiments were conducted in
duplicate. Cells were incubated in 1 ml of Opti-MEM (Invitrogen) with added
10% FBS, Sodium Pyrvate, NEAA, and PenStrep (with or without varying con-
centrations of compound and 10 mM of Cu2+, Zn2+, or Fe3+ as chloride) for 5 hr
at 37C. At the end of the incubation, the media was removed and replaced
with 1 ml PBS to dislodge the cells, which were then put into Eppendorf tubes
and pelleted. The cell pellets were then used for inductively coupled plasma
mass spectrometry (ICPMS) analysis of metal content as previously described
(Maynard et al., 2006).
Dissolution of Zn-Induced Aß Precipitates
Aß1-42 (10 mM) was incubated with ZnCl2 (20 mM) and thioflavin T (ThT) in a mo-
lar ratio of (1:2:2) for 24 hr at 37C on a rotating wheel in PBS (pH 6.6). Following
incubation, the mixture (containing peptide aggregates) was incubated with
test compound for a further 2 hr at 37C with rotation. CQ and PBT2 were dis-
solved in DMSO to a stock concentration of 5 mM. Dilutions were made in
DMSO as appropriate to 100 times the desired final concentration, then added
to the reaction buffer to a final DMSO concentration of 1% v/v PBS. Untreated
aggregates and DMSO controls were included with each experiment. After 2 hr
incubation, samples were measured for ThT fluorescence using an LS55 (Per-
kin Elmer) fluorimeter. Data were generated using FL Winlab software (Perkin
Elmer). Each measurement was performed in triplicate.
Aß-Plaque-Associated Zn Removal
This technique was developed as a variation of previously published protocols
(Lee et al., 2002), here used to directly assess the effects of PBT2 on amyloid-
bound Zn. A female APP/PS1 animal and age-matched non-Tg littermate (16
months old) were euthanized and the brains were immediately removed and
sectioned on a vibratome (WPI Vibroslice) at 200 mm thickness. Multiple sec-
tions through the region occupied by the hippocampus were rinsed in PBS and
then mounted on glass slides. Sections were then covered with the selective
Zn stain Zinpyr-4 (NeuroBioTex, Inc, USA; 10 mM in PBS) for 3 min. Sections
were then rinsed in PBS and viewed under the microscope. This stain labeled
a significant number of plaques in each section from the Tg animal only, which
were subsequently shown to be thioflavin-positive (1% solution in distilled
water), confirming the specificity of the stain for Aß plaques. Individual plaques
were imaged prior to application of PBT2 (n = 17 plaques), SSV control solution
(n = 7), or 3-AQ (n = 12), and then the same plaques were reimaged 5 minutes
later. The signal intensity of given plaques was assessed with the aid of
a counting grid in ImageJ (version 1.38X), and the change in signal between
baseline and 5 minutes postdrug was then quantitated and expressed as a
percentage reduction in plaque fluorescence.
Inhibition of Catalytic H2O2 Generation by Aß:Cu Complexes
This technique was adapted from established protocols (Opazo et al., 2002)
and is a dicholorofuoroscein (DCF)-based fluorometric assay that evaluates
the ability of a test compound to inhibit H2O2 generated by Ab complexed
with Cu. DCF (5 mM in DMSO) (Molecular probes, Eugene, OR) is deacetylated
in the presence of 0.25 M NaOH for 30 min and neutralized at pH 7.4 to a final
concentration of 1 mM. Reactions are carried out in PBS (pH 7.4) in a 96-well
plate. They contain Aß1-42 (50 nM to 1 mM), Cu-glycine chelate (Cu-Gly, pre-
pared by adding CuCl2 to glycine in the ratio of 1:6, then added to the Aß in the
proportion 2Cu-Gly:1Ab), a reducing agent (dopamine, 5 mM), deacetylated
DCF 100 mM, and horseradish peroxidase (1 mM, pH 7.4). The reaction mixture
is incubated at 37C for 60 min. Positive controls are Cu alone and Ab:Cu. The
drugs alone or with Cu (2:1) do not generate or degrade H2O2. Fluorescence is
recorded using a Perkin Elmer LS-55 fluorometer with excitation and emission52 Neuron 59, 43–55, July 10, 2008 ª2008 Elsevier Inc.filters at 485 nM and 530 nM, respectively. H2O2 concentration is established
by comparing fluorescence with the H2O2 (1–2.5 mM) standards in PBS. Inhibi-
tion of H2O2 production is assayed by including selected concentrations of test
compound in the wells. The criteria for acceptance of data are as follows: (1)
test substance must not exhibit autofluorescence, (2) test substance must
not generate intrinsic H2O2, and (3) test substance must not interfere with
the detection system in any other way, e.g. inhibit peroxidase activity. PBT2
and CQ were both tested on three separate occasions and the Cu:drug
complex was also shown to not react with H2O2.
Prevention of Cu-Induced Dityrosine Crosslinked Aß
10 mM Aß1-40 was incubated with 25 mM CuCl2 and 50 mM ascorbic acid (mo-
lar ratio 1:2.5:5) for 1 hr at 37C on a rotating wheel in PBS pH 7.4 (700 ml total
volume). The reaction was stopped by the addition of 200 mM EDTA. The 1 hr
reaction mixture without Cu constituted the negative control. In parallel reac-
tions, CQ and PBT2 were incubated with the reaction components at various
concentrations. The amount of dityrosine crosslinked Aß (Barnham et al.,
2004) was assayed by densitometric quantification ofz9 kDa bands of west-
ern blots probed with 1C3, a dityrosine-specific monoclonal antibody (a kind
gift of Dr. Yoji Kato, Himeji Institute of Technology, Himeji, Japan).
Reversal of Aß-Induced Inhibition of LTP in Hippocampal Slices
C57Bl/6 mice (mixed gender, 14–40 days old) were decapitated under anes-
thesia by halothane inhalation and brains were rapidly removed and chilled
in ice-cold artificial CSF (aCSF). Field potential recordings are made in
350 mm slices of the hippocampus by stimulating and recording in the stratum
radiatum of the CA1 region of the hippocampus. Baseline stimulation intensity
was that required to produce 20%–30% of the maximum slope of the field
excitatory postsynaptic potential (fEPSP) and was calibrated at the beginning
of each experiment. Tetanic stimulation was a 1 s 100 Hz pulse delivered in
substitution for the test stimulus at the test intensity. Data were analyzed offline
using pClamp 8.2. The slope of each fEPSP was determined by linear regres-
sion of the data points following the presynaptic fiber volley. LTP was quanti-
fied by averaging the data points from 55 to 60 min posttetanus for each slice.
Aß1-42 (2 mM in aCSF) together with PBT2 or CQ were added to the slices
for 30 min prior to commencing electrophysiological recordings.
Brain Uptake Studies
Mice were administered CQ or PBT2 (30 mg/kg) by oral gavage in 0.5% w/v
hydroxypropylmethylcellulose, 0.5% v/v benzyl alcohol, and 0.4% v/v Tween
80. Mice were anesthetized with an intraperitoneal injection of ketamine and
xylazine (133 mg/kg and 10 mg/kg, respectively) 4 min prior to blood and brain
harvesting. At 120 min postdose (n = 4 or 5 mice at each time point), 500 ml of
blood was withdrawn by cardiac puncture and transferred into tubes contain-
ing 10 ml of heparin (1000 l U/ml). Blood samples were immediately centrifuged
to obtain duplicate 50 ml plasma samples. Immediately following blood collec-
tion, mice were sacrificed by cervical dislocation and the whole brain was
removed. Brain and plasma samples were stored at 20C for 12 days prior
to analysis. On the day of analysis, the whole brain was homogenized in three
parts of water, and an aliquot of the brain homogenate and plasma was ana-
lyzed for compound concentration by LCMS (Quattro Ultima Pt), with analyti-
cal lower limit of quantitation (LLQ) values for PBT2 at 1 ng/ml (plasma) and
10 ng/g (brain), and for CQ at 5 ng/ml (plasma) and 10 ng/g (brain). Standards
were prepared by spiking blank brain homogenate or plasma. Both samples
and standards were processed by adding acetonitrile to the tissue homoge-
nate or plasma, and centrifuging and injecting an aliquot of the supernatant
onto the LCMS. The concentration of each compound in the brain homogenate
was corrected for the amount of compound remaining in the brain vasculature,
the volume of which was previously determined by administration of the non-
absorbable marker 14C-inulin. Complete recovery (>90%) of PBT2 or CQ from
the brain samples using the described extraction procedure was confirmed by
spiking brain homogenate with either compound to a nominal concentration of
500 mg/l, and comparing the supernatant concentration following protein pre-
cipitation with that measured when the compounds were spiked into the same
matrix following precipitation.
The plasma protein binding for CQ and PBT2 was assessed in mouse
plasma. Aliquots of plasma (990 ml) were spiked with 10 ml of compound (in
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Plasma samples were incubated at 37C for 60 min before separating plasma
proteins from plasma water by ultracentrifugation at 42,000 rpm (Beckman
Rotor type 42.2 Ti) for 4 hr. To determine the fraction of each compound bound
to plasma proteins, the concentrations in the supernatant (i.e., plasma water)
and in uncentrifuged plasma control samples were determined by LCMS.
Behavioral Tests
We utilized the MWM to assess the effects of drug on spatial learning and
memory, as previously described (Adlard et al., 2005). Briefly, after nonspatial
pretraining, animals were subject to 6 days of place discrimination training,
with four trials per day, followed by a probe trial 24 hr later to assess retention
of the task. Data was analyzed using the Ethovision automated tracking
system. There was no significant difference in the swim speed between the
different groups of animals across the study.
IVM
Mice (APP/PS1 or Tg2576 animals) were sedated (atropine 0.5 mg/kg + xyla-
zine 10 mg/kg) and then anesthetized (3%–4% isofluorane carried by oxygen).
Following incisions in the scalp, a 0.75 mm bore hole was made above the right
hippocampus. A sterile 27G guide cannula was then stereotaxically implanted
into the hippocampus and held in place using anchoring bone screws and den-
tal cement. The wound was then sutured around the implant and the animal
was allowed to recover. The microdialysis probes (4 mm long, 38 kDa molec-
ular weight cut off [MWCO] membrane; BASi and CMA), perfused with aCSF
(pH 7.35), were inserted under light anesthesia. The animals were fitted with
a mouse collar and then placed into individual housing chambers (Raturn
Cage System, BioAnalytical Systems) where they remained for the duration
of the experiment. Samples of interstitial fluid were automatically collected
every hour via infusion lines into refrigerated sample collectors at a flow rate
of 0.5 ml/min. Dialysates were then collected in 4 hr bins and subsequently
lyophilized. The starting material and subsequent dialysis samples were west-
ern blotted with WO2 antibody and quantitated against Aß1-42 standards. The
identity of the AßISF immunoreactivity was confirmed by probing with other Aß
antibodies, 4G8 and 6E10. The efficiency of recovery of Aß utilizing this
method was assessed by passing aCSF through a 38 kDa MWCO microdial-
ysis probe immersed in a soluble brain fraction (where the brain was sonicated
in PBS and centrifuged at 100,000 3 g for 30 min, and the supernatant was
removed) of a 12-month-old female APP/PS1 mouse. The percentage recov-
ery of WO2 reactive Aß species in the dialysate was calculated by ([D/S]3100),
where D is the concentration of Aß in the dialysate at a given flow rate and S
is the concentration of Aß in the starting material. The efficiency of our system
was 8.2% ± 1.8% (SEM, n = 6), indicating that either much of the Aß in the brain
soluble fraction exists as homo- or hetero-oligomers of >38 kDa in size, or that
much of the Aß adheres to surfaces or is degraded in passage through the
tubing.
Baseline samples were collected for a period of 8 hr prior to oral gavage of
drug. Drug (PBT2 or CQ) was administered and then samples were collected
for 20 hr.
Tissue Preparation
At the completion of all animal studies (those incorporating behavioral assess-
ment), mice were anesthetized (Lethabarb: pentobarbitone sodium, Virbac)
and transcardially perfused with ice-cold PBS. The brain was then removed,
split into its hemispheres, and frozen on dry ice. The tissues were later thawed,
homogenized (by sonication) in PBS (containing protease inhibitor cocktail,
Sigma), and centrifuged at 100,000 3 g (4C, 1 hr) to collect pellet and super-
natant (soluble) fractions. These were subsequently used for all biochemical
assessments.
SELDI-TOF Mass Spectrometry
PS10 ProteinChip arrays were used for all experiments. Antibody (4G8 in PBS
[0.25 g/l]) and negative control (bovine IgG at the same concentration and vol-
ume) were incubated on the chips in a humidity chamber at 4C overnight. The
antibodies were then removed and blocking buffer (5 ml, 0.5 M ethanolamine in
PBS) incubated on the chip for 60 min. This was then removed and each spot
was washed with 20 ml of 0.5% Triton X-100/PBS (wash buffer) for 5 min andthen 20 ml of PBS for 5 min. Samples were prepared by adding 1 ml of Triton X-
100 and 12.5 ml of 8 M urea to 100 ml of each sample and then mixing. Fifteen
microliters was then added to each spot and the array was incubated at room
temperature (RT) for three hours. The samples were removed and each spot
was rinsed with wash buffer (2 3 50 ml, 10 s), followed by a wash with PBS
(2 3 50 ml, 10 s), and finally, the arrays were washed with 1 mM HEPES (2 3
50 ml, 10 s) and air-dried. All the incubations and washes were performed on
a shaking table. Sinapinic acid (50% [v/v] acetonitrile/0.5% TFA) was applied
to each spot twice, with the chip air-dried between each application. Analysis
was conducted using a PBSIIc, SELDI-TOF mass spectrometry, and peaks
were analyzed using Ciphergen ProteinChip software 3.1.
Western Blot
Western blot was utilized to assess total tau (anti-human total tau, DAKO),
phosphorylated tau (tau phosphorylated at Ser396, Biosource), synaptophysin
(Chemicon), dityrosine (mAb 1C3 [a gift from Dr. Yoji Kato, Himeji Institute of
Technology, Himeji, Japan]), soluble oligomeric Aß using antibody A11 (Kayed
et al., 2003) (a gift from Dr. Charles Glabe, University of California at Irvine,
USA), APP (22C11, Chemicon), and total Aß (WO2, 6E10, 4G8). Samples
were run on NuPage NOVEX Invitrogen bis-tris 4%–12% 26-well gels at 160
V for 1 hr. Membranes were heated in PBS (5 min, microwave), blocked in
TBST (0.01% Tween, 3% BSA), and incubated with antibody overnight
(4C). Blots were rinsed in TBST and then incubated in secondary antibody
(1 hr, RT), followed by further rinsing, development with ECL reagent, and
imaging using a Las-3000 image capture system (Fujifilm).
SUPPLEMENTAL DATA
The Supplemental Data for this article can be found online at http://www.
neuron.org/cgi/content/full/59/1/43/DC1/.
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